台灣臨床試驗主持人資料庫|TPIDB

TPIDB > Principal Investigator

Principal Investigator

National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

National Taiwan University Cancer Center (在職)

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation

更新時間：2023-09-19

林宗哲

Principal Investigator

Clinical Trial Experience (year)

Recruiting Trial

141Cases

Clinical Trials List Publication

請選擇要匯出的欄位

全選

Plan Title (TW)

Plan Title (EN)

Plan No

NCT No

Start Date

End Date

Trial Phase

ICD-9

ICD-10

Applicant

CRO (TW)

CRO (EN)

Trial Scale

Indication (TW)

Indication (EN)

Purpose (TW)

Purpose (EN)

Drug Name (TW)

Drug Name (EN)

ATC Code

Ingredient (TW)

Ingredient (EN)

Dose Type (TW)

Dose Type (EN)

Dose (TW)

Dose (EN)

Evaluation (TW)

Evaluation (EN)

Inclusions (TW)

Inclusions (EN)

Exclusions (TW)

Exclusions (EN)

Taiwan Quantity

Global Quantity

IIT

Hospital

Accept Qty

Contact Name (TW)

Contact Name (EN)

Contact Phone (TW)

Contact Phone (EN)

Contact Email (TW)

Contact Email (EN)

Co-PI

Modify Search

Find Division/Department

Find Hospital

All Location

All Division/Department

All Division/Department
Division of Internal Medicine
Division of Surgery
Division of Others

篩選

Developmental Phase

Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others

Trial Status

Not yet recruiting
Active
Completed

Recruitment Status

Not yet recruiting
Recruiting
Completed
Terminated
Stop recruiting
Suspended
Study ended

Trial scale

Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center

The expected start time interval of the test

Trial Applicant

Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization

Important Roles

Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None

Audit by Sponsors/CRO

Sponsors
CRO
None

Investigator-initiated trial(IIT)

Filters

林宗哲

List

278Cases

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

Condition/Disease

advanced stage hepatocellular carcinoma
Test Drug

Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2015-09-01 - 2019-12-31

Phase III

A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition/Disease

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated4Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

Condition/Disease

TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer
Test Drug

Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2017-10-15 - 2021-06-11

Phase II

A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

Condition/Disease

Metastatic Non-Small Cell Lung Cancer
Test Drug

Keytruda / Epacadostat

Participate Sites
6Sites

Terminated5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-08-07 - 2021-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)

Condition/Disease

Extensive Stage Small Cell Lung Cancer
Test Drug

Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿

China Medical University Hospital-Taipei

未分科

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2014-10-01 - 2023-03-16

Phase III

A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)

Condition/Disease

Non-Small Cell Lung Cancer (NSCLC)
Test Drug

MK-3475

Participate Sites
5Sites

Terminated5Sites

2015-04-01 - 2020-12-31

Phase III

A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine

Condition/Disease

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
4Sites

Terminated4Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-12-14 - 2020-10-31

Phase III

A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)

Condition/Disease

Colorectal Carcinoma
Test Drug

Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated5Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-05-01 - 2020-04-30

Phase III

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

Condition/Disease

Advanced Hepatocellular Carcinoma
Test Drug

Pembrolizumab (MK-3475) /KEYTRUDA

Participate Sites
7Sites

Terminated6Sites

邱昌芳

China Medical University Hospital-Taipei

未分科

林錫銘

Linkou Chang Gung Medical Foundation

Digestive System Department

2015-09-09 - 2017-11-30

Phase III

TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinumdoublet Chemotherapy

Condition/Disease

Non-Small Cell Lung Cancer (NSCLC)
Test Drug

CO-1686 Hydrobromide Film-Coated Tablet

Participate Sites
6Sites

Terminated5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

1 Previous page 20 21 22 23 24 Next page 28

搜尋計畫列表下載細項

全部

試驗主持人
實際收案人數